返回 
加入收藏
我国非处方药市场准入优化路径现状调研及国际经验应用建议
x
请在关注微信后，向客服人员索取文件
| 篇名： | 我国非处方药市场准入优化路径现状调研及国际经验应用建议 |
| TITLE： | Current situation research on the optimization path of market access for over-the-counter drugs in China and suggestions for the application of international experience |
| 摘要： | 目的 为优化我国非处方药（OTC）市场准入流程提供参考。方法在文献调研的基础上设计调查问卷，通过问卷星平台向来自医药企业、药品监管机构、行业协会、医疗机构和高校的受访者发放问卷，对回收的调查数据进行统计分析。结果共回收154份问卷，均为有效问卷。58.5%的受访者来自医药企业，18.8%的受访者来自药品监管领域，另有22.7%的受访者来自高校和医疗机构；超过半数受访者的工作年限≥10年。89.6%的受访者呼吁建立OTC独立审评体系；88.3%的受访者认为有必要建立符合我国国情的OTC专论制度；73.4%的受访者认为应规范专论纳入程序及流程；77.3%的受访者认为应完善处方药转换为OTC的具体流程；91.0%的受访者认为真实世界数据/证据可有助于简化OTC上市路径，但在数据质量和数据获取方面存在难点。结论我国OTC市场准入机制审评周期较长，建议我国可参考国际经验，构建“制度重构-技术革新-监管创新”三位一体的本土化适配优化路径，为建立科学高效的OTC监管体系提供决策依据。 |
| ABSTRACT： | OBJECTIVE To provide a reference for optimizing the market access process for over-the-counter drugs （OTC） in China. METHODS Based on literature review， questionnaire survey was designed and distributed via the Wenjuanxing platform to respondents from pharmaceutical enterprises， drug regulatory agencies， industry associations， medical institutions and universities. The collected survey data were then subjected to statistical analysis. RESULTS A total of 154 questionnaires were collected， all of which were valid. Among the respondents， 58.5% were from pharmaceutical enterprises， 18.8% were from the field of drug regulation， and the remaining 22.7% were from universities and medical institutions. More than half of the respondents had been working for 10 years or more. A total of 89.6% of the respondents called for the establishment of an independent review system for OTC. Additionally， 88.3% believed it was necessary to establish an OTC monograph system based on China’s national conditions. Meanwhile， 73.4% of respondents believed it was necessary to standardize the monograph inclusion procedures and processes， while 77.3% thought the specific process for switching prescription drugs to OTC status should be improved. Furthermore， 91.0% of the respondents considered that real-world data/evidence could contribute to simplifying the OTC market approval pathway， although challenges related to data quality and data accessibility were acknowledged. CONCLUSIONS The review cycle for China’s OTC market access mechanism is relatively long. A localized adaptation and optimization path of “institutional reconstruction-technological innovation-regulatory innovation” in a trinity is proposed to provide a decision-making basis for establishing a scientific and efficient OTC regulatory system with international experience serving as a reference. |
| 期刊： | 2025年第36卷第12期 |
| 作者： | 卢娜；郝海平；丁佐奇 |
| AUTHORS： | LU Na，HAO Haiping，DING Zuoqi |
| 关键字： | 非处方药；市场准入；注册审评；路径优化；国际经验 |
| KEYWORDS： | OTC； market access； registration review； path optimization； international experience |
| 阅读数： | 0 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
